関連する実験動画
Updated: Feb 13, 2026

08:39
Culture of Bladder Cancer Organoids as Precision Medicine Tools
Published on: December 28, 2021
5.5K
膀がんを非活性化された尿病原性E.E.で標的化 coli:BCG免疫療法に対する新しい代替手段
Vladimir Yutkin1, Naseem Maalouf2,3, Chamutal Gur4,5
1Department of Urology, Hadassah Hebrew University Medical School, Jerusalem 91120, Israel.
Cells
|February 12, 2026
まとめ
非活性化尿病原性エシェリキア大腸菌 (UPEC) は,非筋肉侵襲性膀がん (NMIBC) の新しい免疫療法として有望を示しています. この膀がん治療は,バシルス・カルメッテ・ゲーリン (BCG) と比較して優れた有効性と安全性を示しました.
科学分野:
- 腫瘍学 腫瘍学
- 免疫学 免疫学とは
- 泌尿器科 泌尿器科とは
背景:
- 膀がんの90%以上は泌尿器官がん (UC) で,75%が非筋肉侵襲性膀がん (NMIBC) として発現しています.
- バチルス・カルメット・ゲーリン (BCG) は,標準的なNMIBC免疫療法ですが,有効性,再発率,および毒性が限られています.
- より安全で効果的な膀がん治療の必要性が極めて高い.
研究 の 目的:
- 非活性化尿病原性Escherichia coli (UPEC) が,NMIBCに対する腸内免疫療法剤としての可能性を調査する.
- 臨床前膀がんモデルにおけるBCGと比較したUPECの有効性,特異性,免疫依存性,および安全性を評価する.
主な方法:
- オーソトップ性膀がんのモデルは,マウス (MB49-luc) とラット (AY-27) で確立されました.
- 1型フィムブリア変異体を含む,フォーマルデヒドで不活性化されたUPEC菌株は,静脈内投与された.
- 効果,生存,免疫依存 (T細胞),および安全性プロファイルが評価され,BCG.と比較されました.
主要な成果:
- 腸内UPECは,腫瘍の負担を大幅に減らし,ネズミのモデルで生存率を向上させ,BCGを上回った.
- UPECは,ラットにおけるBCGに匹敵する有効性を実証したが,有毒性が著しく低下した.
- 抗腫瘍効果はT細胞に依存し,1型フィムブリアが腫瘍粘着に寄与し,全身UPEC投与は効果がなく,死亡率が増加した.
結論:
- 不活性化UPECは,膀がんに対する強力な,腫瘍を標的とした,T細胞に依存した免疫療法剤です.
- UPECは,現在のBCG免疫療法と比較して優れた安全性プロファイルを提供します.
- 腸内UPECは,NMIBC治療の有望で実用的な代替案です.
関連する概念動画
X-Inactivation
42.7K
The human X chromosome contains over ten times the number of genes as in the Y chromosome. Since males have only one X chromosome, and females have two, one might expect females to produce twice as many of the proteins, with undesirable results.
42.7K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Alternative RNA Splicing
25.3K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
25.3K
Alternative RNA Splicing
5.2K
5.2K
Activation and Inactivation of G Proteins
11.7K
Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high...
11.7K

